| Product Code: ETC8563616 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 New Zealand Lumasiran Market Overview |
3.1 New Zealand Country Macro Economic Indicators |
3.2 New Zealand Lumasiran Market Revenues & Volume, 2021 & 2031F |
3.3 New Zealand Lumasiran Market - Industry Life Cycle |
3.4 New Zealand Lumasiran Market - Porter's Five Forces |
3.5 New Zealand Lumasiran Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 New Zealand Lumasiran Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 New Zealand Lumasiran Market Revenues & Volume Share, By Dosage form, 2021 & 2031F |
3.8 New Zealand Lumasiran Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 New Zealand Lumasiran Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.10 New Zealand Lumasiran Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 New Zealand Lumasiran Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness and acceptance of RNA interference (RNAi) therapies in the medical community. |
4.2.2 Growing prevalence of rare genetic diseases in New Zealand. |
4.2.3 Favorable government policies and regulations supporting the development and adoption of innovative therapies like Lumasiran. |
4.3 Market Restraints |
4.3.1 High cost of Lumasiran treatment may limit accessibility for patients. |
4.3.2 Limited healthcare infrastructure and expertise for administering advanced therapies like Lumasiran in New Zealand. |
4.3.3 Competition from other rare disease treatments in the market. |
5 New Zealand Lumasiran Market Trends |
6 New Zealand Lumasiran Market, By Types |
6.1 New Zealand Lumasiran Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 New Zealand Lumasiran Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 New Zealand Lumasiran Market Revenues & Volume, By Miscellaneous Metabolic Agents, 2021- 2031F |
6.1.4 New Zealand Lumasiran Market Revenues & Volume, By others, 2021- 2031F |
6.2 New Zealand Lumasiran Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 New Zealand Lumasiran Market Revenues & Volume, By Primary Hyperoxaluria, 2021- 2031F |
6.2.3 New Zealand Lumasiran Market Revenues & Volume, By Others, 2021- 2031F |
6.3 New Zealand Lumasiran Market, By Dosage form |
6.3.1 Overview and Analysis |
6.3.2 New Zealand Lumasiran Market Revenues & Volume, By Injection, 2021- 2031F |
6.3.3 New Zealand Lumasiran Market Revenues & Volume, By Solution, 2021- 2031F |
6.4 New Zealand Lumasiran Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 New Zealand Lumasiran Market Revenues & Volume, By Subcutaneous, 2021- 2031F |
6.4.3 New Zealand Lumasiran Market Revenues & Volume, By Demographic, 2021- 2031F |
6.4.4 New Zealand Lumasiran Market Revenues & Volume, By Adult, 2021- 2031F |
6.4.5 New Zealand Lumasiran Market Revenues & Volume, By Pediatric, 2021- 2031F |
6.5 New Zealand Lumasiran Market, By End-Users |
6.5.1 Overview and Analysis |
6.5.2 New Zealand Lumasiran Market Revenues & Volume, By Clinics, 2021- 2031F |
6.5.3 New Zealand Lumasiran Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.5.4 New Zealand Lumasiran Market Revenues & Volume, By Diagnostic center, 2021- 2031F |
6.6 New Zealand Lumasiran Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 New Zealand Lumasiran Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.6.3 New Zealand Lumasiran Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.6.4 New Zealand Lumasiran Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
7 New Zealand Lumasiran Market Import-Export Trade Statistics |
7.1 New Zealand Lumasiran Market Export to Major Countries |
7.2 New Zealand Lumasiran Market Imports from Major Countries |
8 New Zealand Lumasiran Market Key Performance Indicators |
8.1 Patient enrollment in clinical trials for Lumasiran. |
8.2 Number of healthcare professionals trained in administering Lumasiran. |
8.3 Rate of adverse effects reported post-treatment with Lumasiran. |
8.4 Time taken for regulatory approval processes for RNAi therapies in New Zealand. |
8.5 Research and development investments in RNAi therapies in New Zealand. |
9 New Zealand Lumasiran Market - Opportunity Assessment |
9.1 New Zealand Lumasiran Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 New Zealand Lumasiran Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 New Zealand Lumasiran Market Opportunity Assessment, By Dosage form, 2021 & 2031F |
9.4 New Zealand Lumasiran Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.5 New Zealand Lumasiran Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.6 New Zealand Lumasiran Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 New Zealand Lumasiran Market - Competitive Landscape |
10.1 New Zealand Lumasiran Market Revenue Share, By Companies, 2024 |
10.2 New Zealand Lumasiran Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here